July 29th, 2020
Cardiomatics, a portfolio company of INNOventure, has recently been working intensively on the development of its ECG analysis technology. This is partly due to the ongoing pandemic. First of all – medical staff is currently particularly overburdened, so all technologies that help doctors and nurses are gaining interest and popularity. This also applies to telemedicine and AI solutions by Cardiomatics. In addition, the increased need for medical expertise is associated with ongoing research into COVID-19. Cardiomatics technology (and precisely – the AI used in new Cortrium C3+ holter devices) is used in the ACOVID (Arrhythmias in Patients With COVID-19) clinical trial, which is being implemented at Herlev and Gentofte Hospital in Denmark. Researchers are trying to determine to what extent continuous electrocardiographic monitoring of patients with COVID-19 allows for early detection of cardiac complications in the course of the disease and for developing long-term health forecasts for them.
Continuous and long-term (spanning over several days) heart rate records are increasingly used as a diagnostic tool. The fast and accurate analysis of such extensive data sets is a technical challenge that the Cardiomatics R&D team is currently successfully dealing with. Due to the use of IT infrastructure based on GPU servers, analysis times have been reduced by approximately 85%.